Compare Oatly Group AB - ADR (OTLY) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oatly Group AB - ADR vs Tempus AI — how do they compare? Oatly Group AB - ADR trades at $11.93 (market cap $330.93M), while Tempus AI trades at $70.35 (market cap $12.58B). The key difference: Tempus AI is far larger — about 38× Oatly Group AB - ADR's market cap, and Oatly Group AB - ADR is more actively traded (68,708 versus 7,444,569). Which is the better fit depends on your goals — on Pluang, investors hold Oatly Group AB - ADR for 18 Days and Tempus AI for 22 Days on average.
| OTLY | TEM | |
|---|---|---|
Market Cap | $330.93M | $12.58B |
Volume | 68,708 | 7,444,569 |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $15.91 | $99.28 |
52-Week Low | $8.03 | $41.55 |
Typical Hold Time | 18 Days | 22 Days |
Enterprise Value | $835.34M | $13.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OTLY trades at $10.37, down 1.33% today, with mixed technical signals showing bearish moving averages but bullish oscillators. The company reported Q2 2026 revenue growth and raised full-year guidance, though it continues to post significant net losses. Analyst sentiment is divided with a $12.28 consensus price target representing 18% upside potential. Cash flow remains negative but improving, with operating losses narrowing from -$269M in 2022 to -$24M in 2025.
The investment case hinges on OTLY's revenue growth acceleration and path to profitability, but high debt levels and persistent losses present substantial risk. While the stock offers potential upside to analyst targets, investors must weigh the company's improving operational trends against its negative equity and cash burn. The upcoming Q3 2026 earnings report on October 28 will be critical for validating management's turnaround narrative.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite recent weakness. The company reported Q2 2026 revenue growth of 22% year-over-year and beat EPS estimates for three consecutive quarters, though it remains unprofitable with a net income margin of -17.77%. Recent positive developments include FDA clearance for its ECG-MR AI product and expanded data licensing agreements, fueling investor optimism in the healthtech sector.
The investment outlook is cautiously optimistic, driven by strong analyst support (64% buy ratings) and a consensus price target of $72.60, implying modest upside. Key opportunities include accelerating adoption of AI-powered diagnostics and strategic acquisitions, but risks persist from persistent cash burn, insider selling, and intense competition in the precision medicine space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
